2023 position statement on improving management for patients with heart failure in Aotearoa New Zealand

Robert N Doughty1, Gerry Devlin2, Selwyn Wong3

  • 1Heart Foundation Chair of Heart Health and Cardiologist, Department of Medicine, The University of Auckland; Greenlane Cardiovascular Service, Te Whatu Ora - Health New Zealand Te Toka Tumai, Auckland Hospital, Aotearoa New Zealand.

PubMed

Insights

Urgent action is needed to address heart failure inequities in Aotearoa New Zealand. This position statement outlines optimal healthcare delivery and pharmacotherapy to improve health outcomes for all heart failure patients.

Area of Science:

  • Cardiology
  • Public Health
  • Health Equity

Background:

  • Heart failure impacts 1-3% of the population, presenting a significant public health challenge with high hospitalization and mortality rates.
  • Health inequities in heart failure incidence have increased in Aotearoa New Zealand over the past 13 years, disproportionately affecting Māori and Pasifika populations.
  • Contemporary heart failure management guidelines offer clear guidance, yet equitable access to optimal care remains a concern.

Purpose of the Study:

  • To ensure equitable access to optimal healthcare delivery and evidence-based pharmacotherapy for contemporary heart failure management in Aotearoa New Zealand.
  • To address critical areas including access to pharmacotherapy, timely initiation and titration of treatments, and workforce capacity for heart failure care.

Main Methods:

  • This position statement synthesizes current regional and international heart failure guidelines.
  • It focuses on three key areas: access to evidence-based pharmacotherapy, early initiation and titration of treatments, and workforce requirements.
  • The approach emphasizes implementation of evidence-based healthcare strategies.

Main Results:

  • The statement identifies key areas for improving heart failure care delivery.
  • It highlights the need for equitable access to guideline-directed medical therapy.
  • It stresses the importance of timely treatment initiation and titration, supported by adequate workforce capacity.

Conclusions:

  • Implementing evidence-based healthcare strategies is crucial for improving heart failure patient outcomes in Aotearoa New Zealand.
  • Addressing health inequities requires focused action on pharmacotherapy access, treatment timeliness, and healthcare workforce development.
  • Ensuring optimal healthcare delivery will provide all heart failure patients the opportunity for substantial health improvements.

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
340
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
381
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
588
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.5K